Holen Sie sich die Stockscreener-App
30.73
1.84%
0.52
Schlusskurs vom Vortag:
$30.21
Offen:
$29.73
24-Stunden-Volumen:
138.38K
Relative Volume:
0.88
Marktkapitalisierung:
$439.50M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+33.24%
1M Leistung:
+61.92%
6M Leistung:
+179.69%
1J Leistung:
-37.76%
1-Tages-Spanne:
$29.01
$31.33
1-Wochen-Bereich:
$22.02
$32.55
52-Wochen-Spanne:
$6.875
$74.49
Neurogene Inc Stock (NGNE) Company Profile
Firmenname
Neurogene Inc
Sektor
Branche
Telefon
(877) 237-5020
Adresse
535 W 24TH STREET, NEW YORK
Vergleichen Sie NGNE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NGNE
Neurogene Inc
|
30.80 | 431.15M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.56 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
472.79 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.13 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
801.26 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
331.45 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Neurogene Inc Stock (NGNE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-17 | Eingeleitet | Craig Hallum | Buy |
| 2025-05-16 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-06-27 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-06-11 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-04-29 | Eingeleitet | Leerink Partners | Outperform |
| 2024-03-21 | Eingeleitet | William Blair | Outperform |
| 2024-01-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-01-05 | Eingeleitet | Stifel | Buy |
| 2024-01-04 | Eingeleitet | TD Cowen | Outperform |
Alle ansehen
Neurogene Inc Aktie (NGNE) Neueste Nachrichten
Can a trend reversal in Neurogene Inc. lead to recoveryWeekly Stock Recap & Growth Focused Entry Reports - newser.com
Price action breakdown for Neurogene Inc.Trade Volume Report & Capital Efficiency Focused Strategies - newser.com
How to track smart money flows in Neurogene Inc.July 2025 Big Picture & High Return Stock Watch Alerts - newser.com
Why Neurogene Inc. stock is popular among millennials2025 Big Picture & Advanced Swing Trade Entry Plans - newser.com
Does Neurogene Inc. qualify in momentum factor screeningProduct Launch & Reliable Price Action Trade Plans - newser.com
Why Neurogene Inc. stock remains a top recommendationQuarterly Market Summary & Verified Swing Trading Watchlist - newser.com
Neurogene’s (NGNE) Buy Rating Reiterated at HC Wainwright - Defense World
HC Wainwright Reiterates Buy Rating for Neurogene (NASDAQ:NGNE) - MarketBeat
Neurogene (NASDAQ:NGNE) Earns Sell (D-) Rating from Weiss Ratings - MarketBeat
How Neurogene Inc. (UU8) stock responds to job market shiftsJuly 2025 Sector Moves & High Win Rate Trade Tips - newser.com
HC Wainwright & Co. Reiterates Neurogene (NGNE) Buy Recommendation - Nasdaq
Neurogene Reaches Accord With FDA on Plan for Registrational Trial for Rett Syndrome Gene Therapy NGN-401 - CGTLive®
Neurogene Announces Positive Regulatory Update for NGN-401 Gene Therapy in Rett Syndrome with Plans to Initiate Dosing in Fourth Quarter of 2025 - MarketScreener
Neurogene to begin Rett syndrome gene therapy registrational trial in Q4 - Investing.com
Real time pattern detection on Neurogene Inc. stockQuarterly Trade Summary & Advanced Swing Trade Entry Alerts - newser.com
Neurogene Completes FDA Talks for Rett Syndrome Trial - TipRanks
Neurogene : Poster ESGCT2025 RoA Final Print - MarketScreener
23 developmental milestones — Neurogene to start Embolden dosing in Q4 2025 after FDA talks and ICV data - Stock Titan
What recovery options are there for Neurogene Inc.2025 Top Gainers & Low Risk Entry Point Guides - newser.com
Forecasting Neurogene Inc. price range with options dataTrade Exit Summary & Real-Time Stock Entry Alerts - newser.com
What drives Neurogene Inc UU8 stock priceBollinger Bands Signals & Free Explosive Wealth Accumulation - earlytimes.in
Neurogene to Participate in H.C. Wainwright Genetic Medicines Virtual Conference - Stock Titan
What analysts say about Neurogene Inc stockInflation Impact on Stocks & Big Data Market Reports - earlytimes.in
Short interest data insights for Neurogene Inc.July 2025 Highlights & Entry Point Confirmation Signals - newser.com
Is Neurogene Inc a good long term investmentWeekly Market Snapshot & Free Rapid Profit Acceleration - earlytimes.in
Neurogene Insiders Placed Bullish Bets Worth US$1.46m - simplywall.st
Strategies to average down on Neurogene Inc.Portfolio Performance Summary & Free Fast Gain Swing Trade Alerts - newser.com
Long term hold vs stop loss in Neurogene Inc.2025 Year in Review & Momentum Based Trading Ideas - newser.com
Neurogene announces inducement grants under Nasdaq Listing Rule - MarketScreener
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
We're Not Very Worried About Neurogene's (NASDAQ:NGNE) Cash Burn Rate - 富途牛牛
Developing predictive dashboards with Neurogene Inc. dataQuarterly Market Review & Weekly Return Optimization Plans - newser.com
Does Neurogene Inc. stock trade at a discount to peersJuly 2025 Patterns & Free Community Consensus Stock Picks - newser.com
Is Neurogene Inc. trending in predictive chart modelsWeekly Trend Summary & Risk Controlled Daily Trade Plans - newser.com
Neurogene looks ‘deeply undervalued’ after Taysha news, says H.C. Wainwright - TipRanks
Batten Disease Pipeline 2025: Innovative Clinical Developments by 10+ Global Leaders – DelveInsight | Featuring Polaryx Therapeutics, Neurogene, Theranexus, M6P Therapeutics, Regenxbio - The Globe and Mail
Finanzdaten der Neurogene Inc-Aktie (NGNE)
Es liegen keine Finanzdaten für Neurogene Inc (NGNE) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
1.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):